[Ganli Pharmaceutical Industry: application for listing license of Lai preserved Insulin injection accepted by FDA] Ganli Pharmaceutical announced that the company had previously submitted an application for permission for biological products of Lai preserved Insulin injection to the US Food and Drug Administration (referred to as "FDA"), and recently received a notice of formal acceptance from FDA in the United States, entering the substantive review stage. Lai Pu insulin is a kind of quick-acting insulin analogue.